Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis

Next Previous
X
Search
Trial Profile

A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ESK-001 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Alumis

    • Most Recent Events

    • 08 Mar 2025 According to an Alumis media release, the Company announced positive 52-week data from this open-label extension (OLE) study were presented during a late-breaking session at the 2025 American Academy of Dermatology Association (AAD) Annual Meeting in Orlando, Florida.
    • 08 Mar 2025 Results presented in the Alumis media release.
    • 28 Feb 2025 According to an Alumis media release, the Company will give four data presentations from its Phase 2 OLE study evaluating ESK-001, in moderate-to-severe psoriasis (PsO) patients at the 2025 American Academy of Dermatology (AAD) annual meeting from March 7 to 11, 2025, in Orlando, Florida.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top